Drugs
(XML - 5KB)Current Drug Shortages O - R
The information provided in this section is provided voluntarily by manufacturers. FDA cannot require firms to report the reason for shortage or duration of the shortage or any other information about shortages. FDA appreciates all information provided by manufacturers. We post information about shortages as soon as we receive it from the manufacturers. To report information about shortages or supply issues, manufacturers can send updates to drugshortages@fda.hhs.gov. Healthcare professionals and patients are also encouraged to notify us of shortages at drugshortages@fda.hhs.gov.
*Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
APP | 4 mg; 2 mL (NDC 63323-0373-02) | Check Wholesalers for Inventory. Next delivery expected October 2012. | APP currently has both presentations of Ondansetron available. Please check wholesalers for inventory. Shortage per Manufacturer: | Demand increase for the drug. | Revised 10/3/2012 |
| 40 mg; 20 mL (NDC 63323-0374-20) | Available | ||||
Bedford 20 mL vial (NDC 55390-0121-01) | 2 mL vials, packages of 10 (NDC 55390-0121-10) - discontinued | Bedford has ondansetron 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date. Bedford Laboratories has multiple products affected by this temporary suspension of manufacturing. Bedford will have the affected, as well as the available products, listed on their website and are updating this information as it changes. The company voluntarily suspended all manufacturing and distribution in mid-November, 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. Bedford discontinued the following products: Shortage per Manufacturer: | Discontinuation of the manufacture of the drug. | ||
| 2 mL Novaplus vials, packages of 10 (NDC 55390-0307-10) - discontinued | |||||
| 20 mL Novaplus vials, packages of 1 (NDC 55390-0307-01) - discontinued | |||||
| Caraco 313-871-8400 | 2 mL ampules (NDC 62756-0181-01) | Caraco temporarily discontinued ondansetron injection | Discontinuation of the manufacture of the drug. | ||
| 20 mL vials (NDC 62756-0182-01) | |||||
| Hospira, Inc. Customer Service: 1-877-946-7747 | 2 mg/mL; 2 mL vials (NDC 0409-4755-03) | Next delivery mid October Estimated recovery 4Q 2012 | Please check with your wholesaler for available inventory. | Demand increase for the drug. | Revised 10/12/2012 |
| 2 mg/mL; 20 mL vials (NDC 0409-4759-01) | Next delivery December Estimated recovery: December | ||||
| West-Ward (formerly Baxter products) Customer Service: | 2 mg/mL, 2 mL vial (NDC 0641-6078-25) | West-Ward currently has inventory available for both 2 mL and 20 mL vials. Multiple lots are scheduled for manufacturing and release in July and August 2012. | West-Ward has accelerated production and is projecting to have additional units available. Product will be made available as it is released. Shortage per Manufacturer: | Demand increase for the drug. | Revised 7/9/2012 |
2 mg/mL, 20 mL Vial (0641-6079-01) | |||||
| Teva 1-800-545-8800 | 20 mL vials (NDC 00703-7226-01) | Teva has limited inventory | These skus will remain on allocation through the Q412. | Demand increase for the drug | Reverified 10/18/2012 |
| 20 mL vials (NDC 00703-7226-03) | |||||
| 2 mL vials (NDC 00703-7221-04) | |||||
| GlaxoSmithKline Customer Service: 1-888-825-5249 | Zofran injection, 2 mg/mL, 2 mL vials, packages of 5 (NDC 00173-00442-02) | GlaxoSmithKline has the following available: 20 mL vial (NDC 00173-0442-00) GlaxoSmithKline has discontinued Zofran 2 mL vials | Demand increase for the drug. | ||
| 20 mL vial (NDC 00173-0442-00) | |||||
Wockhardt Customer Service: | 2 mg/mL, 2 mL vials, package of 5 (NDC 64679-0726-01) | Wockhardt has existing inventories and no backorder presently | Available | Demand increase for the drug. | Revised 10/12/2012 |
| 2 mg/mL, 20 mL vials, package of 1 (NDC 64679-0727-01) | |||||
Pfizer
| Ondansetron 4 mg/2mL x 25 count (preservative fee, latex free) NDC 0069-1340-16 | Pfizer has the following presentations of ondansetron 2 mg/mL available in limited quantities: 2 mL vials, package of 25 (NDC 0069-1340-16) 20 mL vials, package of 1 (NDC 0069-1340-02) | Demand increase for the drug. | Reverified 6/25/2012 | |
| 40mg/20mL x 1 MDV NDC 0069-1340-02 | |||||
Sagent Pharmaceuticals 1-866-625-1618
| 2 mg/mL 2mL vial (NDC 25021-777-02) | Available | Reverified 10/22/2012 | ||
Ondansetron Injection 32 mg/50 mL premixed bags
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Claris | 32 mg/50 mL (NDC 36000-0014-06) | Pending information Shortage per Manufacturer:
| Other | ||
| Sagent Pharmaceuticals 1-866-625-1618 | 32 mg/50 mL (NDC 25021-0776-50) - discontinued | Sagent has discontinued their ondansetron premixed bags. | Shortage per Manufacturer: Discontinued | Discontinuation of the manufacture of the drug. | Reverified 10/22/2012 |
| Teva Pharmaceuticals 1-800-545-8800 | 32 mg/50 mL (NDC 00703-7239-39) | Teva has ondansetron 32 mg/50 mL premixed bags on back order and the company cannot estimate a release date. |
| Requirements related to complying with good manufacturing practices | Reverified 10/18/2012 |
| Hospira, Inc. Customer Service: 1-877-946-7747 | 0.64 mg/mL; 50 mL bag (32 mg/50 mL) (NDC 0409-4760-24) | Next anticipated delivery and recovery in 2013 | Shortage per Manufacturer: Temporary discontinuation. | Discontinuation of the manufacture of the drug | Reverified 10/12/2012 |
| Baxter Customer Service: 1-888-229-0001 | Ondansetron Injection 32 mg/50 mL premixed bags (NDC 00338-1762-41) | Baxter has issued a voluntary recall and discontinued the manufacture and sale of this product. | New safety information communicated in the FDA Drug Safety Communication issued 06/29/2012 | Discontinuation of the manufacture of the drug | Reverified 9/24/2012 |
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Eisai 1-888-422-4743 | 150 mcg/mL, Eisai 2 mL vial (NDC 62856-0603-01) | Eisai is working to have product available again. | For information on Patient Access Program, please visit: http://www.ontak.com/ Shortage per Manufacturer: | Other |
Oxsoralen (methoxsalen) 1% topical lotion (7/6/2010)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Valeant Pharmaceuticals International 1-866-819-9007 | There is not yet an estimated release date. Shortage per Manufacturer: | Other |
Oxymorphone Hydrochloride Oral Tablet (Initial Posting-3/19/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Roxane Customer Service: 1-800-243-0127 | 5mg tablets, 100 count (NDC 00054-0283-25) | Available | Shortage issue has been fully resolved | Other | Revised 7/14/2012 |
| 10mg tablets, 100 count (NDC 00054-0284-25) | |||||
Endo Pharmaceuticals Inc. | Opana (oxymorphone hydrochloride): 10mg tablet, 100 count bottle (NDC 63481-0613-70) | Temporarily unavailable and Endo cannot estimate a release date at this time. | We will continue to provide updates as further information becomes available. Shortage per Manufacturer: | Shortage of an active ingredient. | Reverified 5/15/2012 |
| Opana (oxymorphone hydrochloride): 5mg tablet, 100 count bottle (NDC 63481-0612-70) | |||||
| Oxymorphone hydrochloride: 10mg tablet, 100 count bottle (NDC 60951-0795-70) | |||||
| Oxymorphone hydrochloride: 5mg tablet, 100 count bottle (NDC 60951-0794-70) |
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Hospira Inc. Customer Service: 1-877-946-7747 | 1 mg/mL; 10 mL vial (NDC 0409-4646-01) | Next delivery December | Shortage per Manufacturer: Manufacturing delay | Other | Revised 10/12/2012 |
Pegasys (peginterferon alfa-2a) Injection - Prefilled Syringes (Initial Posting-3/26/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Genentech Resource Center: 1-877-436-3683 | 180 mcg/0.5 mL Pegasys Prefilled syringe (PFS) for single use (NDC 0004-0352-39) (NDC 0004-0357-30) | Potential limited availability of the PFS form of 180 mcg/mL Pegasys. The firm anticipates that the potential shortage of the PFS will resolve by end of June 2013. | Shortage per Manufacturer: | Other | Revised 9/24/2012 |
| 180 mcg/0.5 mL Autoinjector for single use (NDC 0004-0365-09) | The firm has adequate supplies | ||||
| 135 mcg/0.5 mL Autoinjector for single use (NDC 0004-0360-09) | The firm has adequate supplies | ||||
| 180 mcg/mL Vial for single use (NDC 0004-0350-09) | The firm has adequate supplies |
Pentamidine isethionate inhalant (NebuPent) (Initial posting-8/27/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| APP 1-888-386-1300 | 300 mg, SDV (NDC 63323-0877-15) | APP is currently back-ordered and cannot estimate a release date at this time. | Shortage per Manufacturer: | Shortage of an active ingredient | Reverified 10/3/2012 |
Pentamidine isethionate for injection (Pentam 300) (Initial posting-8/27/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| APP 1-888-386-1300 | 300mg, Lyophilized Powder for Injection (NDC #633230-113-10) | Back-ordered | Shortage per Manufacturer: | Shortage of an active ingredient | Revised 10/3/2012 |
Pentostatin for Injection (Nipent) (Initial Posting - 3/21/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Hospira Inc. Customer Service: 1-877-946-7747 | 10 mg vial (NDC 0409-0801-01 | Available | Shortage per Manufacturer: Available | Revised 10/12/2012 | |
| Bedford Customer Service 1-800-562-4797 10mg vial; ( NDC 55390-0244-01) | Manufacturing Delays | Bedford Laboratories has 10 mg lyophilized powder for injection available in limited quantities. Once this supply is depleted, the next estimated release dates are unknown. Availability of products is updated on the Bedford Laboratories website. | Discontinuation of the manufacture of the drug. | Revised 4/10/2012 |
Perflutren Lipid Microsphere (DEFINITY ) Injection (Initial posting 3-23-12)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
Lantheus Medical Imaging | 4 vial kit (NDC 11994-011-04) | Lantheus has limited supplies available and will release products as it becomes available. | Shortage per Manufacturer: Manufacturing delays at contract manufacturer | Requirements related to complying with good manufacturing practices | Reverified 9/26/2012 |
Phentolamine Mesylate (updated 6/4/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Bedford Customer Service: 1-800-562-4797 | Phentolamine mesylate for injection, 5 mg lyophilized vial (NDC 55390-0113-01) | On backorder | Bedford has phentolamine on backorder and the company cannot estimate a release date. Shortage per Manufacturer: | Discontinuation of the manufacture of the drug. | Reverified 5/29/2012 |
Sandoz Inc 1-800-525-8747 | Phentolamine Mesylate Injection 5mg/mL (boxes of 10-1 mL single dose vials) NDC 00781-3028-95 | Please contact your wholesaler or Sandoz Customer Service at 800-525-8747 for ordering information. | Sandoz in conjunction with FDA has initiated temporary importation of phentolamine mesylate injection into the US market to address this shortage. The Sandoz phentolamine mesylate injection 5 mg/mL product contains the same active ingredient, phentolamine mesylate, as the phentolamine mesylate for injection 5 mg vial product approved in the United States. However, there are important differences between the US product and Canadian product that Healthcare providers should be aware of before prescribing and product preparation. Please see the Dear Healthcare Professional Letter (PDF - 260KB) for additional product and supply information. | Other | Reverified 10/1/2012 |
Phytonadione Injectable Emulsion (Vitamin K)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Hospira, Inc. Customer Service: 1-877-946-7747 | 1 mg/0.5 mL; 0.5 mL amp (NDC 0409-9157-01) | Available | Please check with your wholesaler for available inventory.
Shortage per Manufacturer: | Revised 10/12/2012 | |
| 10 mg/mL; 1 mL amp (NDC 0409-9158-01) | Available | ||||
| Amphastar Pharmaceuticals, Inc./IMS 1-800-423-4136 | 1 mg/0.5 mL, SAF-T-JET prefilled syringe contains polysorbate 80 and propylene glycol
NDC 76329-1240-5 (old NDC 00548-1240-00) | Available | Other | Reverified 9/24/2012 | |
Pilocarpine HCL Opthalmic Gel 4% (Pilopine HS) (Initial posting-6/1/12)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Alcon Customer Service: 1-800-862-5266 | PILOPINE HS (pilocarpine hydrochloride ophthalmic gel) 4% 4 gm tube: (NDC 0065-0215-35) | Unable to estimate a release date | Updates will be provided as further information becomes available. Shortage per Manufacturer: | Other |
Potassium Chloride Injection 2 mEq/mL (Initial posting - 5/15/2012)
| Company | Product | Availability and Estimated Shortageuration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
APP Pharmaceuticals | 2 mEq/mL, 5 mL vials, (NDC 63323-0965-05) | Back-ordered | APP is currently back-ordered on all presentations of potassium chloride and is releasing product intermittently. Shortage per Manufacturer: | Demand increase for the drug. | Revised 10/18/2012 |
2 mEq/mL, 10 mL vials, (NDC 63323-0965-10) | Back-ordered. Next delivery expected November 2012. | ||||
2 mEq/mL, 15 mL vials, (NDC 63323-0965-15) | Unavailable | ||||
2 mEq/mL, 20 mL vials, (NDC 63323-0965-20) | Back-ordered. Next delivery December 2012. | ||||
2 mEq/mL, 30 mL vials, (NDC 63323-0967-30) | Back-ordered. Next delivery November 2012. | ||||
B. Braun Medical Inc. | 2 mEq/mL, 250 mL bulk package (NDC 00264-1940-20) | Available |
| Revised 10/17/2012 | |
Baxter | 10 mEq/100 mL in sterile water (NDC 00338-0709-48) | Available |
| Demand increase for the drug.
| Revised 9/24/2012 |
20 mEq/100 mL in sterile water (NDC 00338-0705-48) | Available | ||||
40 mEq/100 mL in sterile water (NDC 00338-0703-48) | Available | ||||
20 mEq/50 mL in sterile water (NDC 00338-0703-41) | Available | ||||
10 mEq/50 mL in sterile water (NDC 00338-0705-41) | On backorder. Supply recovery expected in early October. | ||||
20 mEq/1000 mL in lactated ringers and dextrose 5% (NDC 00338-0811-04) | Available | ||||
20 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0803-04) | Available | ||||
20 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0691-04) | Available |
| |||
40 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0675-04) | Available | ||||
20 mEq/1000 mL in 5% dextrose (NDC 00338-0683-04) | Available | ||||
40 mEq/1000 mL in 0.9% sodium chloride (NDC 00338-0695-04) | Available | ||||
20 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-04) | Available | ||||
20 mEq/500 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0671-03) | Available |
| |||
20 mEq/1000 mL in 0.45% sodium chloride (NDC 00338-0704-34) | Available |
| |||
40 mEq/1000 mL in 5% dextrose and 0.9% sodium chloride (NDC 00338-0807-04) | Available | ||||
20 mEq/500 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-03) | Available | ||||
20 mEq/1000 mL in 5% dextrose and 0.2% sodium chloride (NDC 00338-0663-04) | Available | ||||
10 mEq/1000 mL in 5% dextrose and 0.45% sodium chloride (NDC 00338-0669-04) | Available | ||||
Hospira, Inc. | 2 mEq/mL; 250 mL bottle (NDC 0409-1513-02) | Next delivery September Estimated recovery: 4Q 2013 | Please check with your wholesaler for available inventory. | Demand increase for the drug. | Revised 10/12/2012 |
2 mEq/mL; 5 mL vial (NDC 0409-6635-01) | Next delivery October/Estimated recovery 1Q 2013 | ||||
2 mEq/mL; 15 mL vial (NDC 0409-6636-01) | Next delivery December/Estimated recovery 1Q 2013 | ||||
2 mEq/mL; 20 mL vial (NDC 0409-6651-06) | Next delivery October Estimated recovery 3Q 2012 | ||||
2 mEq/mL; 20 mL vial (NDC 0409-6653-05) | Next delivery November Estimated 2Q 2012 | ||||
10 mEq/100 mL (NDC 0409-7074-26) | Available | ||||
10 mEq/50 mL (NDC 00409-7075-14) | Available | ||||
20 mEq/100 mL, | Available | ||||
20 mEq/50 mL | Available | ||||
40 mEq/100 mL | Available | ||||
40 mEq/1000 mL | Available | ||||
20 mEq/1000 mL in 0.9% NaCl | Available | ||||
| 20 mEq/1000 mL in 5% dextrose (NDC 00409-7905-09) | Available | ||||
20 mEq/1000 mL in 5% Dex/Lact Ringers (NDC 0409-7119-09) | Available | ||||
10 mEq/500 mL in 5% dex & 0.225% NaCl | Available | ||||
10 mEq/ 500 mL in 5% dex 0.45% NaCl | Available | ||||
20 mEq/1000 mL in 5% dex& 0.225% NaCl | Available | ||||
20 mEq/1000 mL in | Available | ||||
30 mEq/1000 mL in | Available | ||||
40 mEq/1000 mL in | Available | ||||
10 mEq/1000 mL in 5% dex & 0.45% NaCl | Available | ||||
20 mEq/1000 mL in 5% dex & 0.9% NaCl | Available |
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
Hospira Inc. | 3 mMol/mL, 15 mL vial (NDC 0409-7295-01) | Available | Shortage per Manufacturer: | Revised 10/12/2012 | |
| American Regent/Luitpold 1-800-645-1706 | 3 mMol/mL, 5 mL vial (NDC 00517-2305-25) | Unavailable | American Regent//Luitpold is not manufacturing the 5 mL vials and 15 mL vials.
Please check with your wholesaler for available inventory. | Discontinuation of the manufacture of the drug. | Reverified 10/17/2012 |
| 3 mMol/mL, 15 mL vial (NDC 00517-2315-25) | Unavailable | ||||
| 3 mMol/mL, 50 mL vial (NDC 00517-2350-25) | Available |
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Hospira Inc. Customer Service: 1-877-946-7747 | 100 mg/mL; 10 mL vial (NDC 0409-1902-01) | Available | Please check with your wholesaler for available inventory.
Shortage per Manufacturer: manufacturing delay | Other | Revised 10/12/2012 |
500 mg/mL; 2 mL vial (NDC 0409-1903-01) | Next delivery December Estimated 1Q 2013 |
Prochlorperazine Injection (1/30/2012)
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Bedford Customer Service 1-800-562-4797 | 5 mg/mL, 2mL vial, 10 count (NDC 55390-0077-10) | Bedford has both prochlorperazine 5 mg/mL injection presentations on back order and the company cannot estimate a release date. | The 2 mL vials are pending release while the 10 mL vials will not be manufactured until capacity permits. Shortage per Manufacturer:
| Discontinuation of the manufacture of the drug. | |
| 5 mg/mL, 10 mL vial (NDC 55390-0077-01) |
Promethazine Injection (Initial Posting Date) - 2/10/2012
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| Hospira, Inc. Customer Service: 1-877-946-7747 | 25 mg/mL 1 mL Carpuject (NDC 0409-2312-31) | Next delivery 2013 | Shortage per Manufacturer: Manufacturing delay | Other | Reverified 10/12/2012 |
| Teva Phamaceuticals 1-800-545-8800 | 25 mg/mL; 1 mL vial (NDC 00703-2191-04) | Teva has all promethazine injection presentations on back order and the company cannot estimate a release date. | Requirements related to complying with good manufacturing practices | Reverified 10/18/2012 | |
| 50 mg/mL; 1 mL vial (NDC 00703-2201-04 | |||||
| West-Ward Pharmaceuticals Customer Service: 1-800-631-2174 (Formerly a Baxter Product) | Promethazine 1 mL vial, 25 mg/mL (NDC 0641-0928-25) 1 mL vial, 50 mg/mL (NDC 0641-0929-25) 1 mL ampul, 25mg/mL (NDC 0641-1495-35) 1 mL ampul, 50 mg/mL (NDC 0641-1496-35) | West-Ward is currently experiencing a backorder situation on Promethazine 25 mg/mL,1 mL vial, 50 mg/mL, 1 mL ampul and Phenergan 25 mg/mL, 1 mL vial. All other codes are available in limited quantities. West-Ward has accelerated production and will have units of all presentations available for release in the March – April 2012 timeframe. Product will be made available as it is released. Shortage per Manufacturer: | Demand increase for the drug. | Revised 4/24/2012 | |
| Phenergan 1 mL vial, 25 mg/mL (NDC 0641-6084-25) 1 mL vial, 50 mg/mL (NDC 0641-6085-25) 1 mL ampul, 25mg/mL (NDC 0641-6082-25) 1 mL ampul, 50 mg/mL (NDC 0641-6083-25) |
Propofol Injection (Initial Posting Date) - 4/5/2012
| Company | Product | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per New Legislation-FDASIA)* | Date Updated |
|---|---|---|---|---|---|
| APP 1-888-386-1300 | Propofol 20 mL (NDC 63323-270-25) | Check wholesalers for inventory | APP is releasing Propofol ad Diprivan directly into the channel. Please check wholesalers for inventory. Shortage per Manufacturer: | Demand increase for the drug. | Reverified 10/3/2012 |
| Propofol 50 mL (NDC 63323-270-50) | |||||
| Propofol 100 mL (NDC 63323-270-65) | |||||
| Diprivan 20 mL (NDC 63323-269-20) | |||||
| Diprivan 50 mL (NDC 63323-269-50) | |||||
| Diprivan 100 mL (NDC 63323-269-65) | |||||
| Hospira, Inc. Customer Service: 1-877-946-7747 | 10 mg/mL; 20 mL (NDC 0409-4699-30) | Next delivery December Estimated recovery 1Q 2013 | Please check with your wholesaler for available inventory. Shortage per Manufacturer: manufacturing delay | Other | Revised 10/23/2012 |
| 10 mg/mL; 50 mL (NDC 0409-4699-33) | TBD | ||||
| 10 mg/mL; 100 mL (NDC 0409-4699-24) | TBD | ||||
| APP (Fresenius Kabi) 1-888-386-1300 | Fresenius Propoven 1% 20 mL glass ampule | Importation begins early July, with product available in the channel by mid July | APP in conjunction with FDA has initiated temporary importation of Fresenius Propoven 1% (propofol) injection into the US market to address this shortage. Please see the Dear Healthcare Professional Letter (PDF - 614KB)for additional product and supply information. APP is releasing Fresenius Propoven 1% (propofol) directly into the channel as it becomes available. Shortage per Manufacturer: . | Other | Reverified 10/3/2012 |
Fresenius Propoven 1% 50 mL SD Vial | Importation begins early July, with product available in the channel by mid July | ||||
Fresenius Propoven 1% 100 mL SD Vial | Importation begins early July, with product available in the channel by mid July | ||||
